Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03293680 | Pembrolizumab in Elderly Patients With Advanced Lung Cancer | completed | Phase 2 | 83 | Spanish Lung Cancer GroupOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04843007 | Alvopem® (Pemetrexed) Safety Assessment | completed | — | 199 | NanoAlvandINDUSTRY | 0 | Oct 23, 2024 | clinicaltrials |
| NCT04007068 |
| FDG PET/CT Radiomics Analyses of Lung Cancer Patients Treated With Immunotherapy |
| completed |
| — |
| 30 |
| Institute of Oncology LjubljanaOTHER |
| 1 |
| Oct 18, 2024 |
| clinicaltrials |
| NCT02364609 | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib | completed | Phase 1 | 11 | Jonathan RiessOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03004183 | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC(STOMP) | completed | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05383898 | Study to Evaluate D-1553 in Subjects With Lung Cancer | completed | Phase 1 / Phase 2 | 225 | InventisBio Co., LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06313268 | Safety of Effivia®, a Bevacizumab Biosimilar | completed | — | 83 | Laboratorios LiomontINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02955758 | Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | completed | Phase 2 | 25 | Joel NealOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03526900 | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis(ATEZO-BRAIN) | completed | Phase 2 | 40 | Spanish Lung Cancer GroupOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02775435 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | completed | Phase 3 | 559 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 8, 2024 | clinicaltrials |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03822351 | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC(COAST) | completed | Phase 2 | 189 | MedImmune LLCINDUSTRY | 9 | Oct 8, 2024 | clinicaltrials |
| NCT01899989 | Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer | completed | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05569291 | Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Cell Lung Cancer: an Explorative Study(LUCA-coach) | completed | N/A | 19 | Hasselt UniversityOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03875092 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | completed | Phase 3 | 125 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03718117 | Descriptive Observational Study ALK-2016-CPHG(ALK2016CPHG) | completed | — | 73 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03565003 | A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 / Phase 2 | 126 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06607393 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | completed | — | 851 | Aetion, Inc.OTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT02578680 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | completed | Phase 3 | 616 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT02250326 | Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer(abound2L+) | completed | Phase 2 | 240 | CelgeneINDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT02358473 | Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer | completed | Phase 1 | 13 | Kyowa Kirin, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02855125 | A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 | completed | Phase 2 | 128 | Taiho Oncology, Inc.INDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT02864394 | Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) | completed | Phase 3 | 425 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT02927301 | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) | completed | Phase 2 | 181 | Genentech, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04167657 | SinTilimab After Radiation (STAR Study)(STAR) | completed | Phase 2 | 14 | Peking Union Medical College HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04351334 | Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns | completed | — | 161 | PfizerINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04776083 | Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients | completed | Phase 3 | 75 | Menoufia UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05902260 | The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC(NutriCim) | completed | N/A | 51 | Joachim Aerts, MD PhDOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585189 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | completed | — | 304 | Aetion, Inc.OTHER | 0 | Sep 5, 2024 | clinicaltrials |
| NCT03172156 | ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS | completed | — | 100 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT00651833 | Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT00652561 | Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 57 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT02492867 | A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | completed | N/A | 49 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT02664181 | Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial(PRECISE) | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT03971474 | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | completed | Phase 2 | 166 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04173507 | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | completed | Phase 2 | 47 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT05794698 | Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014) | completed | — | 827 | Fudan UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT03664024 | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)(KEYNOTE-782) | completed | Phase 2 | 118 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 22, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02520778 | Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02420314 | Pharmacological Ascorbate for Lung Cancer | completed | Phase 2 | 55 | Joseph J. Cullen, MD, FACSOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04764214 | SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs | completed | Phase 2 | 61 | Fudan UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 23, 2024source: clinicaltrials